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To the Editor: Mediannikov et 
al. recently reported several features 
common to the epidemiology of Rick-
ettsia felis infection and malaria in 
Africa (1). Similar to the findings of 
several other recent studies in Africa 
(2,3), the authors diagnosed R. felis in-
fection in febrile—and to a lesser ex-
tent in afebrile—persons by detecting 
R. felis DNA in human blood samples 
processed by highly sensitive real-
time PCR. These results challenge 
some paradigms in rickettsiology that 
need to be more critically evaluated.
Because R. felis DNA was 
detected in circulating blood of 
asymptomatic persons (albeit more 
frequently in patients with mild fe-
brile illness), Mediannikov et al. pro-
posed that humans could be a natural 
reservoir of R. felis, as they are for 
malaria parasites. R. felis antibodies 
failed to develop in nearly all patients 
in whom R. felis DNA was detected, 
even after repeated detection of R. fe-
lis DNA. In 2 other studies, the same 
researchers proposed that patients 
might have several episodes of R. fe-
lis infection (relapse or reinfection) 
to explain why DNA of the agent 
was detected in the blood at multiple 
times (2,3). They also proposed that 
the absence of an antibody response 
would explain why the disease re-
lapses in some persons (3).
These changing paradigms in 
rickettsiology require thorough evalu-
ation. Once inside a vertebrate host, 
pathogenic rickettsiae have been be-
lieved to multiply primarily within 
endothelial cells in the patient’s or-
gans. As far as we know, rickettsiae do 
not multiply within circulating blood 
cells (4). In contrast, the agents of ma-
laria (Plasmodium spp.) are typically 
parasites of erythrocytes. Therefore, a 
blood sample from a person with ma-
laria is an excellent source for PCR 
diagnostic testing. The sensitivity of 
PCR for rickettsiae in human blood 
samples is very low because the sen-
sitivity depends on the magnitude of 
the vasculitic lesions, i.e., the number 
of endothelial cells destroyed or de-
tached by rickettsial growth, resulting 
in circulating rickettsiae. R. conorii 
(5) and R. rickettsii (6) were detected 
by highly sensitive PCR in 100% of 
fatal cases and in only very few non-
fatal cases.
In addition to never having been 
isolated from humans, R. felis has 
many characteristics of a symbiotic or-
ganism. It possesses a mosaic structure 
genome (size 1.48 Mb) with a high 
coding capacity (83%) that is typical 
of symbiotic bacteria (7). Merhej et 
al. have proposed that within a given 
bacterial genus (including Rickett-
sia), pathogenic species have smaller 
genomes than nonpathogenic spe-
cies (8). In the genus Rickettsia, the 
pathogens R. rickettsii, R. prowazekii, 
R. sibirica, R. typhi, R. parkeri, and 
R. conorii have genomes of ≈1.2–1.3 
Mb, whereas the apparently nonpatho-
genic R. bellii has a 1.5-Mb genome, 
similar to that of R. felis. In contrast to 
the well-known pathogenic Rickettsia 
species, R. felis has been reported in 
a variety of invertebrate hosts, includ-
ing hematophagous (fleas, ticks, flies, 
mosquitoes) and non-hematophagous 
(book lice) arthropods (9). Behar et al. 
have suggested that R. felis is respon-
sible for inducing parthenogenesis in 
book lice, similar to the manner of 
Wolbachia organisms in various in-
vertebrate hosts (9). Furthermore, R. 
felis forms mycetomes in book lice, a 
growth feature typical of bacterial en-
dosymbionts (10).
The current view in rickettsiol-
ogy has a strong anthropocentric bias 
because the studies have concentrated 
on parasitic arthropods that feed on 
humans rather than on free-living ar-
thropods. In fact, the number of Rick-
ettsia species associated with non-
hematophagous hosts might be much 
greater than the ones of medical im-
portance (9). Thus, considering R. fe-
lis as an important pathogen in Africa 
(and in the world) might be premature. 
Several questions need to be answered 
before such a conclusion. In asymp-
tomatic persons in whom endothelial 
cells are likely to be intact, where does 
R. felis grow to be released at detect-
able levels in the circulating blood? 
Considering that all classical spotted 
fever agents induce an antibody re-
sponse (4), why do R. felis antibod-
ies fail to develop in humans after a 
clinical illness attributed to R. felis? 
In addition, repeated reports that the 
main vector of R. felis is the cat flea, 
Ctenocephalides felis, need to be 
proven by experimental demonstra-
tion of its vector capacity.
Given the numerous questions 
about R. felis, we would add another: 
could R. felis be a symbiont of a hu-
man parasite, such as a protozoon or 
a helminth? Obviously, the answer 
is unknown. However, had we not 
known that Wolbachia organisms are 
typically endosymbiotic bacteria of 
both human and animal filarial nema-
todes, what would we conclude if we 
detected Wolbachia DNA in blood of 
either asymptomatic or ill patients?
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Pulmonary Disease 
Caused by  
Mycobacterium 
marseillense, Italy
To the Editor: Mycobacterium 
marseillense was recently described as 
a new species belonging to the Myco-
bacterium avium complex (MAC) (1). 
We describe a case of pulmonary dis-
ease caused by M. marseillense in an 
immunocompetent patient. All strains 
isolated from the patient were prelimi-
narily identified as M. intracellulare; 
however, a retrospective molecular 
analysis corrected the identification to 
M. marseillense.
In December 2005, a 65-year-
old man was admitted to the Univer-
sity Hospital, Modena, Italy, with a 
2-week history of fever, cough, and 
hemoptysis. Physical examination 
detected diffuse rales, and chest ra-
diographs showed a diffuse nodular 
opacity and bronchial thickening, 
confirmed by high-resolution com-
puted tomography (CT) of the chest 
(Figure, panel A). The patient had ex-
perienced several previous episodes 
of hemoptysis and persistent produc-
tive cough since 1998, and tubular 
bronchiectasis had been detected on 
previous high-resolution CT images. 
The patient had a history of thalas-
semia minor, was HIV negative, 
and was formerly a mild smoker (10 
cigarettes/day for 4 years during his 
youth). He had no chronic disorders 
and no history of immunosuppres-
sive-drug or alcohol use.
Bacterial and fungal cultures and 
a smear for acid-fast bacilli performed 
on a bronchoalveolar lavage (BAL) 
sample were all negative. A nontu-
berculous mycobacterium strain was 
isolated by culture and preliminar-
ily identified as M. intracellulare by 
using the GenoType Mycobacterium 
CM/AS Kit (Hain Lifesciences, Ne-
hren, Germany). At that time, a drug 
susceptibility test for isoniazid, ri-
fampin, streptomycin, and ethambutol 
was improperly performed (i.e., was 
not applicable for MAC) by using 
the agar proportion method; sensitiv-
ity information for macrolides was 
unavailable. The strain was resistant 
to ethambutol and susceptible to the 
other drugs. The physician prescribed 
rifampin, isoniazid, and amikacin. 
After remission of fever and hemop-
tysis and improvement of chronic 
cough, the patient was discharged 
from the hospital.
In March 2006, he was readmit-
ted to the hospital for worsening of 
his condition and onset of side effects 
associated with rifampin and isonia-
zid use. The treatment was discon-
tinued and replaced by levofloxacin, 
terizidone, and azithromycin, which 
resulted in remission of symptoms. 
This therapy was continued after hos-
pital discharge.
In 2007, the patient was twice ad-
mitted for follow-up and microbiolog-
ical testing to determine bacteriologic 
status. All 3 separate sputum samples 
were negative for mycobacteria, other 
bacteria, and fungi. However, BAL 
sample culture results were positive 
for the same mycobacterium despite 
continued therapy with levofloxacin, 
terizidone, and azithromycin.
During 2008, as an investigation 
of the possibility of persistent excre-
tion of organisms, additional samples 
were collected 5 times. The sputum 
cultures were intermittently positive, 
while the BAL sample cultures were 
persistently positive.
In May 2009, after the patient 
had been persistently stable and had 
negative culture results for 14 months, 
the antimicrobial drug therapy was 
stopped. In December 2010, the pa-
tient’s only symptom was persistent 
productive cough; however, the spu-
tum culture was again positive, and 
high-resolution CT revealed a wors-
ening condition of his lungs (Figure, 
panel B). A new antimycobacterial 
drug regimen of ethambutol, rifampin, 
and azithromycin was started, in 
accordance with the international 
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